Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating
Bristol-Myers Squibb Company has an average rating of overweight and mean price target of $60.91, according to analysts polled by FactSet. ...